Extracellular vesicles
AssigneeVivaZome Therapeutics Pty Ltd
InventorsDavid HAYLOCK, Ian NISBET, Xenia SANGO, Louise WHITE, Craig NEWTON
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to microRNAs (miRs) and extracellular vesicles comprising same and therapeutic uses thereof, for example, in modulating angiogenesis.
Claims49
A population of gingival fibroblast derived extracellular vesicles.
A method for promoting wound healing in a subject, the method comprising administering an effective amount of gingival fibroblast derived extracellular vesicles to the wound.
A method for promoting tissue repair and/or regeneration in a subject comprising administering an effective amount of gingival fibroblast derived extracellular vesicles to the subject.
A method of treating or preventing an ischemic disease in a subject comprising administering an effective amount of gingival fibroblast derived extracellular vesicles to the subject.
A method of treating or preventing fibrotic disease in a subject comprising administering an effective amount of gingival fibroblast derived extracellular vesicles to the subject.
A population of extracellular vesicles, wherein the extracellular vesicles comprise one or more microRNAs selected from miR-30c-5p, miR-10b-5p, miR-126-5p, miR-25-3p, miR-93-5p, miR-19b-3p, miR-20a, miR-19a-3p, and miR-17-5p.
A population of extracellular vesicles, wherein the extracellular vesicles comprise one or more microRNAs selected from miR-130a-3p, miR-126-3p, miR-150-5p, miR-10b-5p, and miR-126-5p.
Dependencies are inferred from the claim text.